247 related articles for article (PubMed ID: 23331404)
1. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Iwata T; Kawauchi A; Miki T; Fors Z
Int J Urol; 2011 Mar; 18(3):200-5. PubMed ID: 21332814
[TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
4. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
5. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
6. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
7. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
8. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
10. Additional value of PCA3 density to predict initial prostate biopsy outcome.
Ruffion A; Perrin P; Devonec M; Champetier D; Decaussin M; Paparel P; Vlaeminck-Guillem V
World J Urol; 2014 Aug; 32(4):917-23. PubMed ID: 24500192
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
[TBL] [Abstract][Full Text] [Related]
14. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
16. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
[TBL] [Abstract][Full Text] [Related]
19. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
20. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
Bernardeau S; Charles T; Fromont-Hankard G; Irani J
Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
